Supernus Pharmaceuticals, Inc. (SUPN)

Market Cap	1.60B
Revenue (ttm)	597.40M
Net Income (ttm)	-15.51M
Shares Out	54.97M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	16.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	518,381
Open	29.32
Previous Close	29.16
Day's Range	28.70 - 29.32
52-Week Range	21.99 - 35.96
Beta	1.01
Analysts	Buy
Price Target	41.00 (+40.89%)
Earnings Date	May 8, 2024

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 1, 2012
• Employees: 652
• Stock Exchange: NASDAQ
• Ticker Symbol: SUPN

Financial Performance

In 2023, SUPN's revenue was $607.52 million, a decrease of -8.95% compared to the previous year's $667.24 million. Earnings were $1.32 million, a decrease of -97.83%.

Analyst Forecast

According to one analyst, the rating for SUPN stock is "Buy" and the 12-month stock price forecast is $41.0.

Price Target

$41.0

(40.89% upside)

Analyst Consensus: Buy